Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma
Christoph Seidel(Medizinische Hochschule Hannover), Viktor Grünwald(Deutsche Schmerzgesellschaft), Arnold Ganser(Medizinische Hochschule Hannover), Sandra Steffens(Medizinische Hochschule Hannover), Steffen Weikert(St. Hedwig-Krankenhaus), Martin Fenner(PEN American Center), Jonas Busch(Charité - Universitätsmedizin Berlin)
Cited by 54
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k